Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2004-10-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard.2004.028209PMID 15479865PMCID PMC1766782
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C.

  2008cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.

  2004cited by this paper
• A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis

  2004cited by this paper
• Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

  2003cited by this paper
• Polymicrobial septic arthritis in a patient with Wilson’s disease

  2003cited by this paper
• Infections and anti-tumor necrosis factor alpha therapy.

  2003cited by this paper
• Infections and anti–tumor necrosis factor α therapy

  2003cited by this paper
• Infliximab in the treatment of an HIV positive patient with Reiter's syndrome.

  2003cited by this paper
• Epidemiology of hepatitis B in Europe and worldwide.

  2003cited by this paper
• Lack of Tumor Necrosis Factor Alpha Induces Impaired Proliferation of Hepatitis B Virus-Specific Cytotoxic T Lymphocytes

  2003cited by this paper
• EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

  2003cited by this paper
• A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3).

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection

  2003cited by this paper
• Pro‐apoptotic function of HBV X protein is mediated by interaction with c‐FLIP and enhancement of death‐inducing signal

  2003cited by this paper
• Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

  2003cited by this paper
• Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue.

  2002cited by this paper
• Hepatocellular carcinoma and hepatitis C in the United States

  2002cited by this paper
• Course and outcome of hepatitis C

  2002cited by this paper
• Optimal therapy of hepatitis C

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Short Communication: Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factor α, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2

  2002cited by this paper
• Addition of Cyclophosphamide to Antiretroviral Therapy Does Not Diminish the Cellular Reservoir in HIV-Infected Persons

  2002cited by this paper
• Good news for hepatorenal syndrome

  2002cited by this paper
• Optimal therapy of hepatitis C

  2002cited by this paper
• Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

  2002cited by this paper
• Concentrations of Cytokines, Soluble Interleukin-2 Receptor, and Soluble CD30 in Sera of Patients with Hepatitis B Virus Infection during Acute and Convalescent Phases

  2002cited by this paper
• Placebo‐Controlled Trial of Cyclosporin‐A in HIV‐1 Disease: Implications for Solid Organ Transplantation

  2002cited by this paper
• Introduction to therapy of hepatitis C

  2002cited by this paper
• Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2.

  2002cited by this paper
• Course and outcome of hepatitis C

  2002cited by this paper
• Chronic hepatitis B.

  2001cited by this paper
• [Chronic hepatitis B].

  2001cited by this paper
• Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors

  2001cited by this paper
• Hepatitis B e antigen–negative chronic hepatitis B

  2001cited by this paper
• Cytokine regulation of liver injury and repair

  2000cited by this paper
• 10 Worldwide prevalence and prevention of hepatitis c

  2000cited by this paper
• The divergent role of tumor necrosis factor receptors in infectious diseases.

  2000cited by this paper
• Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis.

  2000cited by this paper
• Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis.

  2000cited by this paper
• Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

  2000cited by this paper
• The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

  1999cited by this paper
• Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

  1999cited by this paper
• EASL International Consensus Conference on Hepatitis C

  1999cited by this paper
• Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis.

  1999cited by this paper
• Prevalence of hepatitis C virus infection in the United States.

  1999cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection

  1998cited by this paper
• Hepatitis C

  1998cited by this paper
• [The prevalence of hepatitis C virus infection].

  1998cited by this paper
• Detection of type 2‐like T‐helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity

  1997cited by this paper
• A Double-Blind Placebo-Controlled Phase II Trial of Thalidomide in Asymptomatic HIV-Positive Patients: Clinical Tolerance and Effect on Activation Markers and Cytokines

  1997cited by this paper
• Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha.

  1997cited by this paper
• Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

  1997cited by this paper
• Cytokines and cytokine therapies in HIV infection.

  1997cited by this paper
• The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels.

  1997cited by this paper
• Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.

  1997cited by this paper
• Activation of Tumor Necrosis Factor-α System in Chronic Hepatitis C Virus Infection

  1997cited by this paper
• SERUM LEVELS AND IN SITU EXPRESSION OF TNF-α AND TNF-α BINDING PROTEINS IN INFLAMMATORY LIVER DISEASES

  1996cited by this paper
• Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C

  1996cited by this paper
• Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.

  1996cited by this paper
• Serum levels and in situ expression of TNF-alpha and TNF-alpha binding proteins in inflammatory liver diseases.

  1996cited by this paper
• Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial.

  1996cited by this paper
• Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection.

  1996cited by this paper
• IL-1β and TNF-α produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C

  1996cited by this paper
• Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.

  1996cited by this paper
• IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C.

  1996cited by this paper
• Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection.

  1995cited by this paper
• Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection.

  1995cited by this paper
• Accelerated course of human immunodeficiency virus infection after tuberculosis.

  1995cited by this paper
• Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.

  1995cited by this paper
• Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection.

  1994cited by this paper
• Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis.

  1994cited by this paper
• Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

  1994cited by this paper
• A tumor necrosis factor binding protein (TNF-BP)-physiological antagonist of TNF

  1991cited by this paper
• Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection.

  1991cited by this paper
• Immunohistochemical studies of intrahepatic tumour necrosis factor alpha in chronic liver disease.

  1990cited by this paper
• Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

  1989cited by this paper
• The biology of cachectin/TNF--a primary mediator of the host response.

  1989cited by this paper
• Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.

  1989cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Tratamiento biológico en reumatología

  2025cites this paper
• HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry

  2024cites this paper
• Infections in psoriatic arthritis: association with treatment

  2024influential citation
• Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: long-term safety and follow-up

  2022cites this paper
• Effect of sarcopenia and poor balance on vertebral spinal osteoporotic fracture in female rheumatoid arthritis

  2022cites this paper
• Viral infections in inflammatory bowel disease: Tips and tricks for correct management

  2021cites this paper
• Infecciones asociadas al uso de fármacos anti-TNF en enfermedades reumáticas

  2020cites this paper
• Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies

  2020cites this paper
• A Review of the Use of Biological Agents in Human Immunodeficiency Virus Positive Patients With Rheumatological Diseases

  2020cites this paper
• Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics

  2019cites this paper
• Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update

  2019cites this paper
• Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis

  2019cites this paper
• 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis

  2019cites this paper
• Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease

  2019influential citation
• Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression.

  2019cites this paper
• A Review of Biologics and Other Treatment Modalities in HIV-Associated Psoriasis

  2018cites this paper
• Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study

  2018cites this paper
• Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice

  2018cites this paper
• Soybean-derived Bowman-Birk inhibitor (BBI) blocks HIV entry into macrophages.

  2018cites this paper
• Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity.

  2018cites this paper
• Transaminase Changes in Korean Rheumatoid Arthritis Patients with Chronic Hepatitis C after Biologic Therapy

  2018cites this paper
• Viral Hepatitis B during Chronic Inflammatory Bowel Diseases at Fez University Hospital: Prevalence and Risk Factors

  2018cites this paper
• Safety of biologic agents for psoriasis in patients with viral hepatitis

  2018cites this paper
• Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral Reservoirs

  2017cites this paper
• Inflammatory dermatoses in human immunodeficiency virus

  2017cites this paper
• Serious infections in patients with rheumatoid arthritis treated with tumor necrosis factor alpha antagonist therapy

  2017cites this paper
• Other Psoriasiform Dermatoses in HIV Infection

  2017cites this paper
• Safety profile of biological therapies for treating rheumatoid arthritis

  2017cites this paper
• Cardiac Disease Associated with Human Immunodeficiency Virus Infection.

  2017cites this paper
• Soybean-derived Bowman-Birk Inhibitor (BBI) Inhibits HIV Replication in Macrophages

  2016cites this paper
• Viral Myocarditis and Dilated Cardiomyopathy: Mechanisms of Cardiac Injury, Inflammation, and Fibrosis

  2016cites this paper
• Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS.

  2016cites this paper
• Prevention of HBV reactivation in patients treated with biologic agents

  2016cites this paper
• TNFα Impairs Rhabdoviral Clearance by Inhibiting the Host Autophagic Antiviral Response

  2016cites this paper
• Gastroenterología y Hepatología

  2016cites this paper
• The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis

  2016cites this paper
• (Serious infections in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonist therapy)

  2016cites this paper
• Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues

  2015cites this paper
• HIV / AIDS and rheumatoid arthritis F

  2015influential citation
• Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

  2015cites this paper
• Safety and Efficacy of Etanercept in a HCV/HBV Patient Affected by Psoriasis

  2015cites this paper
• Screening and Vaccinations in Patients Requiring Systemic Immunosuppression: An Update for Dermatologists

  2015cites this paper
• Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study)

  2015cites this paper
• HIV/AIDS and rheumatoid arthritis.

  2015cites this paper
• Sarcopenia in women with rheumatoid arthritis.

  2015cites this paper
• EFFICIENCY OF RECOMBINANT TNF-BINDING PROTEIN FROM VARIOLA VIRUS IN A MODEL OF COLLAGEN-INDUCED ARTHRITIS

  2014cites this paper
• Risk of infections with biological agents.

  2014cites this paper
• Preventing infective complications in inflammatory bowel disease.

  2014cites this paper
• Proinflammatory signaling regulates hematopoietic stem cell emergence.

  2014cites this paper
• The use of ustekinumab in a patient with severe psoriasis and positive HBV serology*

  2014cites this paper
• Exploring Interaction of TNF and Orthopoxviral CrmB Protein by Surface Plasmon Resonance and Free Energy Calculation

  2014cites this paper
• HIV and rheumatology : a practical guide

  2014cites this paper
• A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C

  2014cites this paper
• Revista4Vol89ingles-_Layout 1

  2014cites this paper
• The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.

  2013cites this paper
• Chronic hepatitis C virus hepatitis and psoriasis: No longer a contraindication to interferon use in the era of biological agents?

  2013cites this paper
• Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.

  2013cites this paper
• Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients

  2013cites this paper
• TNF and TNF Receptor Superfamily Members in HIV infection: New Cellular Targets for Therapy?

  2013cites this paper
• Molecular Mechanisms of Interaction between Human Tumor Necrosis Factor and CrmB TNF-binding Proteins of Cowpox and Variola Viruses

  2013cites this paper
• Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral α en la enfermedad inflamatoria intestinal (2013)

  2013cites this paper
• Tumor necrosis factor-α antagonists: Side effects and their management.

  2013cites this paper
• The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

  2013cites this paper
• Sekundäre Immundefizienz bei rheumatologischen Erkrankungen

  2013cites this paper
• Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis.

  2013cites this paper
• The Influence of Anti-TNF Therapy on the Course of Chronic Hepatitis C Virus Infection in Patients with Inflammatory Bowel Disease

  2013cites this paper
• Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations.

  2013cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012

  2013cites this paper
• The safety of anti-TNF therapy in patients with hepatitis B and C virus infection

  2012cites this paper
• Biologics in oral medicine: principles of use and practical considerations.

  2012cites this paper
• Rheumatoid arthritis and the era of biologic therapy

  2012cites this paper
• Efficacy of tumour necrosis factor‐α antagonists in aphthous ulceration: review of published individual patient data

  2012cites this paper
• Producción y polimorfismos de las citoquinas IL-10, IL-6, TNF-α, IFN-γ Y TGF-β en pacientes con hepatitis crónica C genotipo 1 y su relación con la IL-28B y la respuesta al tratamiento antiviral

  2012cites this paper
• PYODERMA GANGRENOSUM ASSOCIATED WITH CHRONIC HEPATITIS C SUCCESSFULLY TREATED WITH ETANERCEPT

  2012cites this paper
• Management of rheumatic disease with comorbid HBV or HCV infection

  2012cites this paper
• Gastroprotective activities of Turnera diffusa Willd. ex Schult. revisited: Role of arbutin.

  2012cites this paper
• Consensus guidelines for the management of plaque psoriasis.

  2012cites this paper
• Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs

  2012cites this paper
• Maintaining the balance: costimulatory TNFRs and control of HIV.

  2012cites this paper
• Biologic Therapy in Psoriasis: Perspectives on Associated Risks and Patient Management

  2012cites this paper
• Use of biological disease‐modifying anti‐rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B

  2012cites this paper
• Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature

  2012cites this paper
• A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier

  2012cites this paper
• role in the treatment of certain rheumatologic diseases dur- ing HCV therapy. While etanercept is generally well toler- ated, potential toxicities include serious infections, increased malignancy risk, cytopenias, and neurologic side effects.

  2011cites this paper
• Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases.

  2011cites this paper
• Bronchiectasis and autoimmune disease

  2011cites this paper
• The Complex Management of Viral-Related Autoimmune Diseases

  2011cites this paper
• Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.

  2011cites this paper
• Hepatitis C virus treatment complicated by rheumatoid arthritis.

  2011cites this paper
• Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab

  2011cites this paper
• Liver diseases associated with anti‐tumor necrosis factor‐alpha (TNF‐&agr;) use for inflammatory bowel disease

  2011cites this paper
• Tumour necrosis factor‐α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients

  2011cites this paper
• Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era.

  2011cites this paper
• Immune modulation of rheumatoid arthritis.

  2011cites this paper
• [Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab].

  2011cites this paper
• Etanercept therapy in a hepatitis B virus (HBV)‐positive psoriatic patient developing a monoclonal gammopathy of undetermined significance

  2011cites this paper
• Treatment with tumor necrosis factor-alpha antagonists and infections

  2011cites this paper
• Safety of anti‐tumour necrosis factor‐α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature

  2011cites this paper
• [IFN-alpha-induced psoriatic arthritis and HCV-related liver cirrhosis. Therapeutic options and patient's opinion].

  2011cites this paper
• [How does one manage patients with rheumatoid arthritis and positive serology to hepatitis B, hepatitis C, human immunodeficiency virus?].

  2011cites this paper